Integra LifeSciences Holdings Corporation
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 1.54B | 1.56B | 1.54B | 1.61B | 1.64B | 1.5% | |
| Cost of Revenue | (597.81M) | (587.36M) | (656.84M) | (728.47M) | (790.01M) | 8.4% | |
Gross Profit | 944.64M | 970.31M | 884.74M | 882.06M | 845.23M | -4.2% | |
| Operating Expenses | |||||||
| Research & Development | (93.05M) | (101.19M) | (104.19M) | (115.38M) | (98.97M) | -14.2% | |
| Selling, General & Administrative | (637.45M) | (616.32M) | (656.64M) | (716.98M) | (699.70M) | -2.4% | |
| Depreciation & Amortization | (123.67M) | (121.11M) | (123.51M) | (140.50M) | (151.05M) | 7.5% | |
Operating Income (EBIT) | 197.23M | 238.92M | 111.53M | 28.41M | 68.32M | 140.5% | |
| Non-Operating Items | |||||||
| Interest Income | 6.74M | 11.92M | 17.20M | 20.04M | 18.47M | -7.8% | |
| Interest Expense | (50.40M) | (49.59M) | (51.38M) | (70.63M) | (86.25M) | 22.1% | |
| Other Income/Expenses (Net) | 17.45M | -25.03M | -30.46M | -46.65M | -631.82M | 1254.4% | |
Income Before Tax | 214.68M | 213.89M | 81.07M | -18.24M | -563.50M | 2989.9% | |
| Income Tax Expense | (45.60M) | (33.34M) | (13.33M) | (11.29M) | (47.03M) | 316.4% | |
Net Income | 169.07M | 180.55M | 67.74M | -6.94M | -516.47M | 7337.7% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $2 | $2 | $1 | $-0 | $-7 | 7361.2% | |
| Weighted Avg Shares Outstanding | 84.70M | 83.00M | 78.17M | 77.01M | 76.75M | -0.3% | |
| Weighted Avg Shares Outstanding (Diluted) | 85.48M | 83.52M | 80.34M | 77.01M | 76.75M | -0.3% | |
EBITDA | 366.33M | 384.60M | 255.96M | 193.29M | -326.20M | -268.8% |
Explore IART
IART in the Healthcare
Small Cap